National Vision (EYE)
(Delayed Data from NSDQ)
$14.90 USD
-2.97 (-16.62%)
Updated May 8, 2024 04:00 PM ET
After-Market: $14.89 -0.01 (-0.07%) 7:44 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.90 USD
-2.97 (-16.62%)
Updated May 8, 2024 04:00 PM ET
After-Market: $14.89 -0.01 (-0.07%) 7:44 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Zacks.com featured highlights include: Intuit, National Vision, Lindsay Corp, Magnolia Oil & Gas and Buckle
by Zacks Equity Research
Zacks.com featured highlights include: Intuit, National Vision, Lindsay Corp, Magnolia Oil & Gas and Buckle
Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.
Medtronic's (MDT) DEFINE AFib Study to Assess AF Burden
by Zacks Equity Research
Medtronic (MDT) begins first app-based study to understand atrial fibrillation burden in patients, utilizing data collected from the LINQ range of insertable cardiac monitors.
5 Top-Performing Liquid Stocks for Attractive Returns in 2021
by Zacks Equity Research
Here are five top-ranked liquid stocks -- Intuit (INTU), National Vision (EYE), Lindsay Corporation (LNN), Magnolia Oil & Gas (MGY) and Buckle (BKE) -- which investors can tap for attractive returns.
Bio-Rad (BIO)-Seegene Pact to Provide Diagnostic Suit In U.S.
by Zacks Equity Research
Bio-Rad (BIO) and Seegene team up to develop and commercialize molecular diagnostic products in the United States.
West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about West Pharmaceutical's (WST) solid proprietary products segment.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
Bowen Center Expands Access to Care via NextGen's (NXGN) Platform
by Zacks Equity Research
NextGen's (NXGN) platform is likely to expand care to the underserved patient pool by improving the access to and delivery of whole-person care.
Amedisys' (AMED) Contessa Buyout to Boost Home Health Business
by Zacks Equity Research
Amedisys (AMED) inks deal to acquire Contessa Health to boost home health and hospice services business.
3 Reasons to Add AMN Healthcare (AMN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about AMN Healthcare (AMN) due to its broad array of services and strength in staffing service.
3 Best MedTech Growth Stocks to Bet On in 2021 Amid Pandemic
by Trina Mukherjee
Grab these three top stocks, EYE, WST and HSIC, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about West Pharmaceutical (WST) due to its solid proprietary products segment.
Abbott (ABT) CE-Marked Panbio Test Now Widely Offered in Europe
by Zacks Equity Research
Abbott's (ABT) Panbio COVID-19 Antigen Self-Test is expected to facilitate mass screenings and aid in resumption of daily life activities with the gradual reopening of economies worldwide.
Abbott (ABT) Reports Late-Breaking Data on FreeStyle Libre
by Zacks Equity Research
Late-breaking data on Abbott's (ABT) FreeStyle Libre system demonstrates improvement in health and equity outcomes for diabetes patients.
Charles River (CRL) Advances in Gene Therapy With Vigene Buyout
by Zacks Equity Research
The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.
Here's Why You Should Buy National Vision (EYE) Stock Now
by Zacks Equity Research
Investors remain optimistic about National Vision (EYE) on increased eyeglass comparable demand and encouraging 2021 strategies.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.
Medtronic (MDT) Diabetes Arm Grows With Favorable InPen Data
by Zacks Equity Research
Medtronic's (MDT) InPen is a FDA as well as CE Mark-cleared smart insulin pen available for patients who require multiple daily injections.
Pacific Biosciences (PACB)-RCIGM Tie Up for Sequencing Research
by Zacks Equity Research
Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.
SmileDirectClub (SDC) Reels Under Cyber Attack, Pandemic Woes
by Zacks Equity Research
SmileDirectClub (SDC) apprehends systems outage to have an adverse impact on its second-quarter revenues to the tune of approximately $10-$15 million.
Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.
Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout
by Zacks Equity Research
Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.
Boston Scientific (BSX) Eyeing Remaining 73% Farapulse Stake
by Zacks Equity Research
Boston Scientific (BSX) currently holds an equity stake of roughly 27%.
Medtronic (MDT) Global Market Share Rises Amid Pandemic Blues
by Zacks Equity Research
Most of Medtronic (MDT) end markets are gradually returning to near-normal pre-COVID growth.
OPKO Health (OPK) and Nicoya Sign RAYALDEE Deal
by Zacks Equity Research
OPKO Health's (OPK) subsidiary EirGen Pharma to develop and commercialize RAYALDEE in Greater China in collaboration with an affiliate of Nicoya Therapeutics.